We report the results of a genome-wide search in a four-generation pedigree with autosomal dominant early-onset dementia (mean onset age: 64.9 years, range 53-79 years). In this family we previously excluded the known Alzheimer's disease genes based on linkage analysis and mutation screening of the amyloid precursor protein gene (exons 16 and 17) and the presenilin 1 and 2 genes. In addition we excluded mutations in the prion protein gene and exons 9-13 of the microtubule associated protein tau (MAPT) gene. We obtained conclusive linkage with chromosome 17q21 markers with a maximum multi-point LOD score of 5.51 at D17S951 and identified a candidate region of 4.8 cM between D17S1787 and D17S958 containing MAPT. Recent clinical and neuropathological follow-up of the family showed that the phenotype most closely resembled frontotemporal dementia (FTD) characterized by dense ubiquitin-positive neuronal inclusions that were tau negative. Extensive mutation analysis of MAPT identified 38 sequence variations in exons, introns, untranslated regions and the 5Ј regulatory sequence, however none was comprised within the disease haplotype. Although our findings do not entirely exclude a mutation in a yet unanalyzed region of MAPT, the apparent absence of MAPT mutations combined with the lack of tau pathology is highly suggestive for another defective gene at 17q21 responsible for FTD in this family.
Introduction
Autosomal dominant early-onset (Ͻ65 years) dementia is a rare type of cognitive deterioration in adulthood. Mutations in the amyloid precursor protein gene (APP, MIM 104760) 1 and the presenilin 1 and 2 genes (PSEN1, MIM 104311; PSEN2, MIM 600759) [2] [3] [4] explain between 20 and 70% of the occurrence of autosomal dominant early-onset Alzheimer's disease (AD). [5] [6] [7] Other important autosomal dominant early-onset dementias include familial Creutzfeldt-Jakob's disease (CJD) and familial frontotemporal dementia (FTD). While all familial CJD cases are caused by molecular defects in the prion protein gene (PRNP, MIM 176640), 8 recent studies have shown that 10-43% of all familial FTD cases are associated with mutations in the gene encoding the microtubule associated protein tau (MAPT, MIM 157140). [9] [10] [11] [12] Because of the substan-tial clinical overlap and phenotypic heterogeneity in these autosomal dominant dementias, 13 careful neuropathological brain examination is crucial in establishing a definite diagnosis. For CJD this implies the demonstration of prion deposits, while both ␤-amyloid plaques and tau-positive neurofibrillary tangles are a prerequisite for the neuropathological diagnosis of AD. FTD can be pathologically classified into three different categories: 14 FTD with neuronal and glial tau depositions, FTD with ubiquitin-positive inclusions, and FTD with neuronal loss and spongiosis but without intracellular inclusions. Clinically there are no features that can reliably distinguish between these three groups. In brains of FTD patients carrying a MAPT mutation, accumulation of the tau protein is a consistent pathological feature. Although FTD is therefore often classified as a primary tauopathy, it is important to note that 64% of the FTD patients do not display tau-pathology as shown by immunohistochemistry, and lack of distinctive histopathology. Together with the relatively low MAPT mutation frequency in familial FTD this suggests that other pathogenetic mechanisms and defective genes resulting in FTD without tauopathy are to be expected. The existence of genetic locus heterogeneity in FTD is already illustrated by a Danish FTD family lacking distinctive neuropathological features, linked to the centromeric region of chromosome 3 (MIM 600795). 15 More recently a set of families with both FTD and amyotrophic lateral sclerosis were linked to 9q21-22 (MIM 105550). 16 Molecular genetic studies of such autosomal dominant FTD families without tau pathology is therefore likely to contribute to our molecular understanding of these highly disabling disorders.
In this study we present results of a genome-wide scan in one multiplex family, family 1083, with autosomal dominant dementia, that was not linked to the known AD loci on chromosomes 14, 19 and 21.
17 Also mutations were not detected in APP (exons 16 and 17), PSEN1, PSEN2, PRNP and MAPT (exons 9-13) (Dermaut et al, unpublished data). 6, 18 In a recent follow-up study it was shown that the phenotype in family 1083 most closely resembled that of FTD, and a neuropathological study of one patient revealed taunegative, ubiquitin-positive neuronal inclusions. Although we observed strong linkage to a 4.8-cM region at 17q21 containing MAPT, we did not detect mutations in MAPT despite extensive screening, suggesting that the tauopathy negative FTD in family 1083 might be caused by a variation in another distinctive gene within 17q21.
Materials and methods

Subjects
Family 1083 has been ascertained in a genetic epidemiological study of early-onset AD in the Netherlands between 1980-1987, 17 using a study protocol approved by the Medical Ethical Committee of the Erasmus Medical Center Rotterdam. For all patients, detailed data on family history of dementia in first-, second-and third-degree relatives were collected by interviewing a next-of-kin of the patient. Four deceased individuals (II-1, II-2, III-3 and III-9) were considered affected based on their clinical course. All living relatives were screened for dementia using the Mini Mental State Examination. 19 Blood samples were obtained and DNA was extracted using a standard phenol-chloroform extraction procedure. Lymphoblast cell lines were established by Epstein-Barr virus transformation.
Linkage to known AD loci on chromosomes 14, 21 and 19 was examined and linkage to 14q24.3, containing PSEN1 was excluded. 17 In the proband mutations in PSEN1, PSEN2 and APP were also excluded by RT-PCR analysis and genomic sequencing. 6 Also, direct sequencing of the coding region of PRNP (Dermaut et al, unpublished data), and of exons 9-13 coding for the microtubule binding domains of MAPT 18 did not reveal mutations. The apolipoprotein E (APOE) genotype of all available family members was determined using PCR amplification and digestion with HhaI, 20 and indicated that all had the APOE ⑀3⑀3 genotype 17 (and this paper).
An extensive clinical follow-up of the family was conducted by neurological examination of patients (III-21 and III-31) and interviewing first-degree relatives.
Molecular Psychiatry
Available medical records and CT scans were also reviewed. The updated pedigree is shown in Figure 1 and detailed clinical characteristics of 12 patients are summarized in Table 1 . In patient III-4 brain autopsy was performed.
Neuropathology
Of the formalin-fixed brain of patient III-4, paraffinembedded sections from all cortical regions, hippocampus and parahippocampal gyrus, amygdala, substantia nigra, basal ganglia, thalamus, cerebellum, and brainstem were processed for routine staining (hematoxylin and eosin (HE), Bodian-silver) and immunohistochemistry. A conventional avidin-biotinperoxidase complex method (Zymed Laboratories, San Francisco, CA, USA) was used, with diaminobenzidine as chromogen. Slides were counterstained with Mayer's hematoxylin and mounted in entellan.
Monoclonal (MC) and polyclonal (PC) antibodies raised against tau, both phosphorylation dependent (AT8, MC, 1:40, Innogenetics, Gent, Belgium; AT180, MC, 1:500, Innogenetics; AT270, MC, 1:500, Innogenetics; PHF1, MC, 1:500, gift from Peter Davies, Albert Einstein College of Medicine, New York, NY, USA; MC1, MC, 1:25, also a gift by Peter Davies), and phosphorylation independent (BR01, MC, 1:500, Innogenetics; Tau2, MC, 1:100, Sigma, St Louis, MO, USA) were used, as well as antibodies against ubiquitin (PC, 1:500, Dako, Glostrup, Denmark), polyglutamine (1C2, MC, 1:1000, Chemicon, Temecula, CA, USA), Human Leucocyte Antigen-DR (HLA-DR, MC, 1:100, Dako), ␣-BCrystallin (PC, 1:500, Novocastra Laboratories, Newcastle upon Tyne, UK), amyloid-␤ (␤A4, MC, 1:100, Dako), ␣-synuclein (PC, 1:500, Chemicon), ␤-tubulin (TUB 2.1, MC, 1:500, Sigma), glial fibrillary acidic protein (GFAP, MC, 1:500, Dako), synaptophysin (1:100, PC, Dako), microtubule associated protein (MAP2, MC, 1:100, Boehringer, Mannheim, Germany), neurofilament (SMI-32, 1:1000, Sternberger Monoclonals, Lutherville, MD, USA) and the prion protein (PrP [27] [28] [29] [30] , PC, 1:200, Chemicon). Heat-induced antigen retrieval was performed by heating slides at 80°C for 30 min in 0.1 M sodium citrate buffer at pH 7.7 for several antibodies (polyglutamine, HLA-DR, ␤-tubuline, synaptophysin, MAP2, GFAP, BR01, and Tau2). Tissue sections were pretreated with 90% formic acid for 5 min prior to incubation with ␤A4-antibody.
Genome-wide scan
A total of 40 DNA samples of members of family 1083 were included in the genetic analysis: eight patients, three spouses and 29 at-risk individuals. In the genome-wide scan we used the 400-microsatellite markers of the ABI Prism Linkage Mapping Set MD-10 Version 2 (Applied Biosystems, Foster City, CA, USA). The PCR amplification protocol and the pooling of differently labeled fluorescent PCR products were in accordance with the manufacturer's instructions. An additional 20 (CA) n -repeat markers spanning a 32-cM region at 17q11-q22 were selected from the Marshfield sex-average linkage map (Genome data base), and used to fine map the candidate region. Two novel CA-repeats located within MAPT were identified using the Tandem repeat finder program. 21 All microsatellite markers were analyzed on an automated ABI377 or ABI3700 DNA-analyzer (Applied Biosystems). For allele identification and scoring we used GENESCAN and GENO-TYPER software (Applied Biosystems), while CEPH marker allele frequencies and numbering were used.
Simulation and linkage analyses
To estimate the power to detect conclusive evidence for linkage in family 1083, we performed a simulation study using the computer program SLINK. 22, 23 A hypothetical marker with six equally frequent alleles was used to generate 400 replicates assuming both linkage at a recombination distance () of 0.05 and non-linkage ( = 0.50). Linkage analysis between the disease locus and the hypothetical marker was calculated assuming autosomal dominant inheritance and an allele frequency of 0.001 for the disease mutation. Six penetrance classes were used, based on the cumulative risk Molecular Psychiatry curve calculated from the mean onset age in the family, with a maximal disease penetrance of 85% at age 85 years or older. The unaffected at-risk individuals were assigned a disease penetrance class according to their age at last interview. Phenocopy rates were also agedependent, based on the literature. 24 All individuals with a phenotype of FTD or a mixed phenotype of FTD with AD and/or vascular dementia were considered affected in the analysis, including patient III-23, who had a stroke but became demented at later age. The phenotype of individuals II-6, II-8 and III-20 who suffered a stroke was considered unknown. Under these conditions we obtained a simulated maximum LOD score of 4.63 and an average maximum LOD score of 1.80. Under the assumption of non-linkage a LOD score Ն1 was observed in 1.6%, and a LOD score Ն2 in 0.2% of the replicates with a maximum LOD score of 2.06.
Two-point and multi-point LOD scores were calculated with the same parameters as in the simulation study using MLINK, ILINK and LINKMAP of the computer package LINKAGE version 5.1, 25 assuming equal recombination rates for males and females.
Mutation analysis
Mutation analysis of MAPT was performed on genomic DNA of exons 1-14 using flanking intronic primers. More than 1 kb of 5Ј regulatory sequence (positions g.-68900 to g.-67600 with transcription initiation site at g.-67924) including exon 0, 26 was analyzed using overlapping primer sets. Intron 13 (927 bp) was amplified with primers located in exons 13 and 14. Standard 25 l PCR reactions with empirically defined optimal annealing temperatures were performed. PCR products were purified with 10 U exonuclease I (USB Corporation Cleveland, OH, USA) and 2 U Shrimp Alkaline Phosphatase (USB Corporation). DNA sequence was determined by cycle sequencing using the 'BigDye Terminator Cycle Sequencing' kit (Applied Biosystems) and analyzed on an ABI3700 DNA analyzer (Applied Biosystems). New sequence variations in exon 0 and the upstream regulatory sequence, were confirmed by PCR-RFLP assays, and allele frequencies of new polymorphisms were determined in 106 unrelated individuals.
Semi-quantitative PCR of exons 10 and 12 of MAPT were performed in multiplex PCR reactions with fluorescent-labeled primer pairs amplifying the respective exons together with a control fragment. The number of PCR cycles was limited to 20 cycles of 30 s at 94°C, 30 s at 60°C and 30 s at 72°C each. The intensities of the fluorescent PCR products were compared on an automated ABI3700 DNA-analyzer.
Results
Family description
Six family members developed dementia after the original report in 1994, 17 including patient III-11 with parkinsonism reported earlier (Figure 1 ). Detailed clinical information was available for 12 of the 16 (eight men, eight women) patients (Table 1 ). The mean age at onset in the 12 patients was 64.9 years (range 53-79 years), with mean disease duration of 6.6 years (range 3-13 years). Restlessness or roaming (eight patients), hyperorality (seven patients), and disinhibition (five patients) were the most common presenting symptoms. Language dysfunction most frequently consisted of echolalia or reduced spontaneous speech, eventually resulting in mutism in all patients. Other symptoms were memory problems early in the course of the disease in four patients, and paranoia in three patients. Lobar atrophy on CT scan was present in two patients (frontal and temporal in III-29, and frontal in III-21), whereas the CT scan was normal 1 year after onset in III-11. Psychometric testing performed in two patients (III-11 and III-21, both 1 year after onset of disease) showed increased distractibility and impaired recall but intact recognition and spatial and temporal orientation. The clinical presentation was highly suggestive for FTD in eight patients, whereas AD and/or vascular dementia could not be excluded in four patients.
Neuropathological description
Macroscopic examination of the brain of patient III-4 showed atrophy of frontal lobes with severely dilated ventricles (brain weight 1450 g). Variable neuronal loss and microvacuolar changes were present in the superficial layers of the frontal cortex, with moderate gliosis of sub-pial and subcortical regions (Figure 2a ). In the temporal cortex similar changes were seen in several patches, intermingled with normal cortex. Furthermore, mild neuronal loss was seen in the Cornu Ammonis of the hippocampus and the entorhinal cortex. A moderate number of age-related neurofibrillary tangles in the pyramidal cells of the entorhinal cortex were present, but no neurofibrillary degeneration was observed in any other cortical region. The parietooccipital cortex and cerebellum were normal. Mild loss of pigmented neurons was seen in the substantia nigra, while striatal regions and thalamus were not affected. No neuritic or diffuse amyloid plaques, ballooned cells, Pick bodies or Lewy bodies were detected.
Staining with ubiquitin antibody showed small numbers of cytoplasmic neuronal inclusions and a moderate number of ubiquitin-positive neurites in the second layer of the frontal and temporal cortex (Figure 2b ). The inclusions, not visible with conventional HE and Bodian-silver staining, were usually crescent-shaped and located preferentially in the perikaryal space directly surrounding the nucleus. A few ubiquitinpositive inclusions appeared to be located within the nucleus and had a cat-eye or target shape ( Figure  2c) . 27, 28 Neurons in the dentate gyrus and subcortical white matter did not contain any cytoplasmic ubiquitin-positive inclusions (Figure 2d ). Antibodies against tau, α-synuclein, neurofilament (SMI-32), ␤-tubulin, MAP2, polyglutamine (1C2) and the prion protein (PrP 27-30 ) did not stain the inclusions. No amyloid plaques or ballooned cells were detected with ␤A4 antibody or ␣B-crystallin respectively. Staining with GFAP antibody showed reactive astrocytosis in superficial cortical layers, as well as in subcortical white matter.
Chromosome 17 linkage
We performed a 10-cM genome-wide scan, and calculated two-point LOD scores for each marker. Only one marker, D17S1868 at 17q21, gave a conclusive LOD score of 3.48 at = 0.00. The centromeric marker, D17S798, showed a positive LOD score of 0.94 at = 0.09. To define the candidate region containing the disease gene based on meiotic recombinants, 22 additional chromosome 17 microsatellite markers spanning a 32 cM region between D17S1857 and D17S787 at 17q11-q22 were analyzed for linkage ( Table 2 ). The highest two-point LOD score of 4.69 was obtained with D17S951 in the absence of recombinants. Multi-point LOD score analysis between D17S1787 and D17S958 provided a maximum LOD score of 5.51 in the interval D17S1789-D17S951-D17S1860 on top of marker D17S951 ( = 0) (data not shown).
Using the genotype data of 26 markers, haplotypes were reconstructed taking into account minimal intermarker recombination (Figure 3) . For deceased relatives genotype data in the offspring were used to reconstruct their haplotypes. The risk haplotype was present in all dementia patients including the patient with FTD and parkinsonism (III-11). The risk haplotype was also observed in four patients (III-22, III-23, III-26 and III-31) for whom AD and/or vascular dementia could not be excluded. Two stroke patients (II-6 and II-8) and individual II-3 who are obligate carriers also segregated the risk haplotype. Individual II-3 died before the mean onset age in the family of an unrelated disease. The founders (I-1 and I-2) died at age 76 years with no reported history of dementia. While most patients shared a common haplotype for all markers spanning the 32-cM region, obligate recombinants defined a candidate region of 4.8 cM between D17S1787 (III-11, III-25 and III-30) and D17S958 (III-11).
Mutation analysis of MAPT
We performed an extensive mutation analysis of exons 1-14 of MAPT in seven patients segregating the risk haplotype and one unrelated control individual. Included were exons 6 and 8 that are not expressed in human brain, 29, 30 and exon 4A encoding 'big tau' in the peripheral nervous system. [31] [32] [33] In addition we analysed exon 0 and 1 kb of 5Ј regulatory sequence comprising different neuronal promoter elements, 34 and intron 13 that is retained in human MAPT transcripts. 26 No mutations explaining the disease phenotype were observed. However, we identified 12 known single nucleotide polymorphisms (SNPs) in the coding Molecular Psychiatry region. In exon 0 and the 1 kb upstream regulatory sequence, seven novel sequence variations as well as the known-221G/C (g.-68142CϾG) were detected. 35 All novel sequence variations were confirmed by PCR-RFLP analysis (Table 3) . Analysis of these new polymorphisms in 50 unrelated control chromosomes showed complete linkage disequilibrium between all seven polymorphisms. The allele frequency of variation g.-68289 G>C was estimated at 77% (G-allele) by PCR-RFLP in 212 unrelated control chromosomes. In addition we observed 20 intronic sequence variations none of which involved splice site consensus sequences.
Segregation analysis of the different MAPT polymorphisms indicated that the risk haplotype in family 1083 contained the common MAPT haplotype H1 defined by polymorphic alleles in exons 1, 2, 3, 9, 11 and 13. 36 All patients were homozygous H1H1 except patients III-22 and III-26 who were heterozygous H1H2 ( Figure  3) . At least one polymorphism in each MAPT exon was detected except in exons 10 and 12. For the latter two exons we used a semi-quantitative PCR-assay to demonstrate that two copies of these two exons were present.
Discussion
Here we described the clinical and pathological followup data of a four-generation Dutch family, first reported in 1994, 17 with autosomal dominant early-onset dementia. In the initial report the proband was described with a clinical diagnosis of early-onset AD Markers from the 10 cM density genome scan are in bold. For additional markers all alleles observed in 1083 were assigned equal allele frequencies. The genetic distances were deduced from the Marshfield sex-averaged Linkage Map.
at age 59 years. At that time no autopsy data were available. Follow-up analysis of 12 patients identified eight patients with a clinical presentation that was highly suggestive for FTD, whereas AD or vascular dementia could not be excluded in four patients. Mean onset age Allele frequencies were estimated in 212 unrelated control chromosomes. The frequency of the rare allele located on the MAPT H2 haplotype was estimated to be 23%.
in the family was 64.9 years (range 53-79). In one autopsied patient we demonstrated complete lack of tau neuropathology and presence of ubiquitin-positive, tau-negative neuronal inclusions as the most important neuropathological characteristics. We conducted a 10-cM density genome-wide scan in family 1083, showed conclusive linkage (multipoint LOD score of 5.51 at D17S951) to chromosome 17q21 and identified obligate recombinants between D17S1787 and D17S958 defining a candidate region of 4.8 cM that contained MAPT. However, an extensive mutation analysis of MAPT coding and splice-site regions did not identify disease-related mutations. Also, deletions of MAPT exon(s) were excluded. Sequence analysis of 1 kb of 5Ј regulatory region and of exon 0, identified seven novel sequence variations none of which were disease-related. MAPT is a candidate gene for a number of genetically unexplained neurodegenerative brain disorders with tau pathology (tauopathies), including progressive supranuclear palsy (PSP) (MIM 601104), corticobasal degeneration (CBD) and lateral sclerosis parkinsonism dementia complex of Guam. [37] [38] [39] [40] Genetic association studies suggested that these disorders might be caused by variations in regulatory elements altering the expression levels of MAPT. Recently a sequence comparison of human MAPT and mouse Mtapt promoter regions showed that the 1-kb region 5Ј to exon 0 is highly conserved between mouse and human (Ͼ67%), including the 335 bp (g.-68260 to g.-67925) immediately 5Ј to exon 0. 26 The sequence variations we identified in the MAPT regulatory region are both SNPs and small insertions/deletions of which the variant allele was always comprised within the rare MAPT haplotype H2. Although none of these variations explained the earlyonset dementia in family 1083, these polymorphisms might have an effect on the expression levels of the different tau isoforms, with potential implications for one of the above-mentioned tauopathies.
The candidate region identified in FTD family 1083 overlaps with that previously reported for FTDP-17 families. At an international consensus conference, in shown between brackets. For confidentiality reasons haplotypes are shown only for patients, the number of at-risk individuals included in the genotyping are within diamonds. The risk haplotype was arbitrarily set for I-1. An asterisk (*) denotes that DNA was available for genotyping.
13 FTD families with overlapping clinical and neuropathological features linked to chromosome 17q21-q22, a critical region of 2 cM between D17S791 and D17S800 was defined. 41 It was also agreed that these families were best described as frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). In nine FTDP-17 families mutations in MAPT were identified. 10 The linkage, clinical and pathological data of the four remaining families without MAPT mutations are summarized in Table 4 . In two families (HDDD2 and Dutch III) with conclusive 17q21-q22 linkage, informative recombinants were identified (Figure 4) . 27, 42 The minimal candidate interval was 18.5 cM between D17S798 and D17S941 in family HDDD2 (Figure 4 ). 42 Family 1083 described in this paper, represents the fifth FTD pedigree without MAPT mutations. With a multi-point LOD score of 5.51 at D17S951, family 1083 is the most informative FTD family linked to 17q21 (Table 4) . Also, the 4.8-cM candidate region between D17S1787 and D17S958 identified in family 1083, significantly reduced the candidate interval for tau-negative FTD at 17q21 (Figure 4 ). To date, mutations in MAPT were identified only in FTDP-17 families with pathological tau depositions. 10 All five FTD families described in Table 4 had no distinctive tau pathology in agreement with the absence of mutations in MAPT. In two families (1083 and Dutch III), ubiquitin-positive inclusions were observed. The remaining three FTD families (Karolinska, HDDD2 and Seattle B) had, apart from neuropathological features of FTD, no other distinctive histopathology, 42, 43 except one (Seattle B) in which numerous amyloid plaques were observed. 44 The mean onset age, mean age at death and disease duration in family 1083, were most comparable with those in families HDDD2 and Dutch III ( Table 4 ). The other two families (Karolinska and Seattle B) had onset ages that were approximately 10 years earlier (early fifties) with narrower onset age ranges. Also, a very rapid progression of disease was reported for the Karolinska family with average disease duration of 3 years. 43, 45 It is important to note however that the Karolinska and Seattle B families did not show conclusive 17q21 linkage (Table 4 ).
In conclusion, in family 1083 we provided significant linkage evidence for a gene at 17q21 and strongly reduced the candidate region to a 4.8 cM interval comprising MAPT. No disease-related MAPT mutations (Table 4 ). Dashed lines indicate that the disease gene could be in a region that extends beyond the map shown, or that genetic linkage analysis with markers from this chromosomal region was not performed.
were detected in exons, flanking intronic sequences, untranslated regions and 1 kb of 5Ј regulatory region making it unlikely that MAPT is involved in the pathogenesis. We also excluded mutations in the recently described novel putative gene Saitohin within intron 9 of MAPT 46 (data not shown). The clinical presentation within family 1083 was most consistent with FTD though some cases with a mixed phenotype of FTD with AD and/or vascular dementia were also observed. Brain pathology in one patient confirmed the clinical diagnosis of FTD but tau depositions were not observed. Most characteristic about the histopathology were the ubiquitin-positive intraneuronal inclusions. At least two other tau-negative FTD families were reported with conclusive linkage to 17q21-q22 in the absence of MAPT mutations, 27, 42 of which one also showed ubiquitin inclusions. 27 Together, these data suggest that another gene may be responsible for taunegative FTD linked to 17q21. Identification of this gene might contribute to our understanding of the genetic etiology and pathogenesis of FTD and its relation to other neurodegenerative brain diseases.
